Research brief · Metabolic
Tirzepatide
Dual GIP/GLP-1 agonist used to study incretin synergy, adipose biology and insulin sensitivity in laboratory models.
Class
Dual GIP/GLP-1 receptor agonist
Half-life
~120 h (5 days)
Studied in
Energy expenditure, lipid metabolism, insulin sensitivity.
What it is
Tirzepatide is a 39-amino-acid synthetic peptide engineered as a balanced dual agonist of the GIP and GLP-1 receptors. Its C20 fatty diacid moiety enables albumin binding and supports an extended half-life suitable for chronic-exposure research.
Mechanism studied
Co-activation of GIP and GLP-1 receptors for incretin pathway studies.
Research notes
- Comparative studies frequently benchmark tirzepatide against semaglutide for incretin pathway crosstalk.
- Used in lipidomic and mitochondrial biogenesis research panels.
Before sourcing any material
- Confirm a lot-matched third-party certificate of analysis (HPLC purity and mass-spectrometry identity).
- Check the stated peptide content per vial, not just the gross vial mass.
- Plan reconstitution volumes first so the vial size matches your protocol.
- Verify what is lawful in your jurisdiction — these are in-vitro research reagents, not medicines.